sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate
OSMOPREP (sodium phosphate, dibasic, anhydrous; sodium phosphate, monobasic, monohydrate) by Bausch Health is clinical pharmacology osmoprep tablets, a dosing regimen containing 48 grams of sodium phosphate (32 tablets), induces diarrhea, which effectively cleanses the entire colon. First approved in 2006.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
OsmoPrep is an oral tablet containing sodium phosphate (dibasic anhydrous and monobasic monohydrate) approved in 2006 for bowel cleansing prior to colonoscopy. It works through osmotic effect, drawing water into the colon to promote evacuation and effective colonic purgation lasting 1–3 hours per dose. The 48-gram regimen (32 tablets) induces diarrhea to cleanse the entire colon.
Product approaching loss of exclusivity with minimal linked job openings signals reduced commercial investment and smaller marketing footprint.
CLINICAL PHARMACOLOGY OsmoPrep Tablets, a dosing regimen containing 48 grams of sodium phosphate (32 tablets), induces diarrhea, which effectively cleanses the entire colon. Each administration has a purgative effect for approximately 1 to 3 hours. The primary mode of action is thought to be…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing
Worked on OSMOPREP at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
Zero linked job openings and approaching LOE signal that career growth opportunities on this product are limited and declining. Professionals joining the OsmoPrep team should expect a defensive, cost-focused role in a shrinking commercial organization preparing for generic transition.